Filing Summary
Business Context and Reporting Period
This Form 6-K was furnished by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, for April 2024 (Report No. 3). The filing reports an April 19, 2024 press release concerning Nasdaq listing status. The request metadata identifies the company as Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Developments
- Nasdaq staff issued a determination to delist NLS Pharmaceutics’ securities.
- The company stated that it intends to request a hearing before a Nasdaq panel.
- The filing does not state the specific basis for the delisting determination, the applicable deadlines, or the expected timing of any hearing.
Guidance, Outlook, Risks, and Unusual Items
The principal disclosed risk is potential loss of Nasdaq listing. The filing does not provide management guidance, operating outlook, financial contingencies, or additional details regarding the consequences of a delisting.
The report incorporates the filing by reference into specified Form F-3 registration statements. Exhibit 99.1 is the referenced press release, but its substantive text is not included in the provided filing content.
Investor Verification Items
- Verify the specific grounds for Nasdaq’s staff delisting determination.
- Confirm the deadline and status of the company’s hearing request.
- Review any Nasdaq panel decision and the potential impact on trading and shareholder liquidity.
- Obtain and review Exhibit 99.1 for details omitted from the filing text provided.